Nanjing Vazyme Biotech Co Ltd (688105) — Capital Reinvestment Ratio
Nanjing Vazyme Biotech Co Ltd (688105) has a Capital Reinvestment Ratio of 0.21x as of September 2025, meaning it reinvests 0% of its operating cash flow (CN¥75.30 Million) in capital expenditures (CN¥15.83 Million). See 688105 equity financing ratio to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Nanjing Vazyme Biotech Co Ltd Capital Reinvestment Ratio (2019–2025)
This chart tracks Nanjing Vazyme Biotech Co Ltd's Capital Reinvestment Ratio across 6 annual periods. Check 688105 total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Nanjing Vazyme Biotech Co Ltd (2019–2025)
Year-by-year Capital Reinvestment Ratio for Nanjing Vazyme Biotech Co Ltd from 2019 to 2025. For live market cap and broader valuation context, see 688105 company net worth.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.20x | CN¥233.16 Million | CN¥47.39 Million | ▼ -82.7% |
| 2023 | 1.17x | CN¥198.40 Million | CN¥232.90 Million | ▼ -10.4% |
| 2022 | 1.31x | CN¥735.17 Million | CN¥962.86 Million | ▲ +208.4% |
| 2021 | 0.42x | CN¥616.80 Million | CN¥261.96 Million | ▲ +123.7% |
| 2020 | 0.19x | CN¥803.55 Million | CN¥152.54 Million | ▼ -85.5% |
| 2019 | 1.31x | CN¥15.20 Million | CN¥19.88 Million | — |